Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
GPC-201 by GPCR Therapeutics for Multiple Myeloma (Kahler Disease): Likelihood of Approval
GPC-201 is under clinical development by GPCR Therapeutics and currently in Phase II for Multiple Myeloma (Kahler Disease). According to...